Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q2 2026 › vs Q2 2025
Cumberland Pharmaceuticals (CPIX) Q2 2026 vs Q2 2025 (year over year)
Cumberland Pharmaceuticals's revenue fell $2.0M (-19%) from $10.8M in Q2 2025 to $8.8M in Q2 2026. The biggest changes: Talicia +$2.3M (—); Kristalose −$1.7M (-61%); Sancuso −$1.3M (-42%).
Cumberland Pharmaceuticals, Q2 2026: revenue $8.8M (-19% year over year), operating margin -35.9%, net loss $4.3M, operating cash flow $169K. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 1.5% | 7.5% | -6.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Talicia | $2.3M | $0 | $2.3M | — |
| Sancuso | $1.8M | $3.1M | −$1.3M | -42% |
| Vibativ | $1.7M | $2.7M | −$963K | -36% |
| Caldolor | $1.5M | $1.6M | −$114K | -7% |
| Kristalose | $1.1M | $2.8M | −$1.7M | -61% |
| Other revenue | $222K | $492K | −$271K | -55% |
| Acetadote | $137K | $194K | −$57K | -29% |
| Revenue | $8.8M | $10.8M | −$2.0M | -19% |
| Net loss | $4.3M | $735K | $3.5M | +481% |
| Costs & expenses | $13.1M | $14.0M | −$887K | -6% |
| Operating costs | $12.0M | $14.0M | −$2.0M | -14% |
| Interest & other, net | $1.1M | −$2.4M | $3.5M | — |
| Income tax | $4K | $6K | −$2K | -32% |
| Research & development | $772K | $837K | −$65K | -8% |
| General & admin | $2.5M | $2.7M | −$110K | -4% |
| Other operating costs | $8.6M | $4.2M | $4.4M | +104% |
| Operating cash sources | $4.4M | $1.6M | $2.9M | +181% |
| Share-based compensation | $78K | $81K | −$3K | -3% |
| Working capital & other | $4.4M | $1.5M | $2.9M | +191% |
| Net loss absorbed | $4.3M | $735K | $3.5M | +481% |
| Operating cash flow | $169K | $844K | −$675K | -80% |
| Free cash flow (OCF − capex) | $130K | $817K | −$687K | -84% |
| Capital expenditures | $38K | $26K | $12K | +45% |
Questions
How much did Cumberland Pharmaceuticals's revenue grow year over year in Q2 2026?
Cumberland Pharmaceuticals's revenue fell $2.0M (-19%) from $10.8M in Q2 2025 to $8.8M in Q2 2026.
What drove Cumberland Pharmaceuticals's revenue change in Q2 2026?
Talicia +$2.3M (—); Kristalose −$1.7M (-61%); Sancuso −$1.3M (-42%).